• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Denali Capital Acquisition Corp.

    2/7/25 4:10:36 PM ET
    $DECA
    Blank Checks
    Finance
    Get the next $DECA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Denali Capital Acquisition Corp.

    (Name of Issuer)


    Class A ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)


    G6256B106

    (CUSIP Number)


    01/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    Meteora Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    498,798.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    498,798.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    498,798.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    39.53 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    G6256B106


    1Names of Reporting Persons

    Vik Mittal
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    498,798.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    498,798.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    498,798.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    39.53 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Denali Capital Acquisition Corp.
    (b)Address of issuer's principal executive offices:

    437 Madison Avenue, 27th Floor, New York, NY 10022
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Meteora Capital, LLC, a Delaware limited liability company ("Meteora Capital") with respect to the Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Meteora Capital serves as investment manager (collectively, the "Meteora Funds"); and (ii) Vik Mittal, who serves as the Managing Member of Meteora Capital, with respect to the Common Stock held by the Meteora Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office for each of the Reporting Persons is: 1200 N Federal Hwy, #200, Boca Raton FL 33432
    (c)Citizenship:

    Meteora Capital is a Delaware limited liability company. Vik Mittal is a United States citizen.
    (d)Title of class of securities:

    Class A ordinary shares, par value $0.0001 per share
    (e)CUSIP No.:

    G6256B106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    498,798
    (b)Percent of class:

    39.53  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    498,798

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    498,798 Meteora Capital, LLC held 498,798 through a redemption of shares available to public shareholders where 3,785,992 shares were redeemed. Prior to the redemption Meteora Capital, LLC owned 11.6% of the outstanding float.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Meteora Capital, LLC
     
    Signature:/s/ Vik Mittal
    Name/Title:Vik Mittal - Managing Member
    Date:02/07/2025
     
    Vik Mittal
     
    Signature:/s/ Vik Mittal
    Name/Title:Vik Mittal - Managing Member
    Date:02/07/2025
    Exhibit Information

    Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 7, 2025 Meteora Capital, LLC By: /s/ Vik Mittal Vik Mittal | Managing Member Vik Mittal By: /s/ Vik Mittal Vik Mittal | Managing Member

    Get the next $DECA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DECA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DECA
    SEC Filings

    View All

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/22/25 5:10:19 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form S-4/A filed by Denali Capital Acquisition Corp.

    S-4/A - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/21/25 5:17:32 PM ET
    $DECA
    Blank Checks
    Finance

    Denali Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)

    4/15/25 9:20:12 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Denali Capital Global Investments Llc

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:05:57 AM ET
    $DECA
    Blank Checks
    Finance

    SEC Form 4 filed by Large owner Xu Jiandong

    4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)

    9/16/24 10:01:42 AM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a busines

    6/11/25 8:30:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

    5/9/25 4:00:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

    NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit

    4/14/25 4:35:00 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DECA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    12/6/24 4:17:05 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 5:49:50 PM ET
    $DECA
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

    SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

    11/14/24 2:35:09 PM ET
    $DECA
    Blank Checks
    Finance

    $DECA
    Financials

    Live finance-specific insights

    View All

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

    As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator

    11/6/24 12:24:36 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

    Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with

    10/28/24 6:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

    Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile

    10/16/24 4:00:00 AM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care